Exonate is proud to announce that we have been shortlisted for the prestigious UKBAA Awards in the Best Investment in a High Growth Female Founder category.
Now in its 14th year, the annual UKBAA Angel Investment Awards celebrate high growth and success in the angel and early-stage investment market – recognising the fastest growing brands and acknowledging the founders, angels, crowd funders and early-stage venture capital investors behind them. Open to both companies and investors, these Awards seek to recognise the year’s most disruptive new market entrants and provide a definitive list of the most exciting ‘ones to watch’ in the angel and early-stage investment space.
Winners will be announced at the UKBAA Investment Awards Dinner, taking place on the 19th June, in the awe-inspiring Liverpool Cathedral, which will bring together over 400 leading players from across the early-stage investment community to join in celebrations.
This year the UKBAA were inundated with an extremely high standard of entries and Exonate’s pitch was deemed to be one of the best. This is a great achievement for Exonate and underlines the Company’s commitment to developing a revolutionary, game changing eye drop for the treatment of retinal vascular diseases, including wet Age-related Macular degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies.
For further information please go to our new website: www.exonate.com